Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 19:04:34时区推断·⟳ 抓取 19:05:46·⚡ 决策 07-29 19:06:35 +49s·89.9 天前
TScan首例患者接受TSC-101三期ALLOHA-2试验给药
TScan Therapeutics（TCRX.US）宣布TSC-101三期AML/MDS试验首例患者给药，属于研发推进的正面但程序性里程碑。
📄 原文Investing.com↗ 原文
TScan doses first patient in phase 3 AML, MDS trial
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10% WALTHAM, Mass. - TScan Therapeutics Inc. (NASDAQ:TCRX)…
不做 TScan Therapeutics（TCRX.US）
三期首例给药是程序性临床进展，顶线数据要到2028年中，当前没有疗效、监管或商业化增量，短线edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 low · price-in 风险 medium ↗
关键理由
- TScan Therapeutics（TCRX.US）宣布TSC-101三期AML/MDS试验首例患者给药，属于研发推进的正面但程序性里程碑。
- 该试验预计到2028年中才有顶线数据，当前事件不改变短期收入、利润或商业化现金流。
- 首例给药本身通常弱于临床读出、FDA批准或重大合作授权，难以形成可回测的短线正期望。
主要风险
- 若公司后续披露安全性、入组速度或中期数据超预期，需由新信号重新评估。
- 临床期生物科技股盘前流动性和跳空波动较大，程序性进展不适合追价。
原文全文
展开原文 · 1,769 字
S. Korea’s KOSPI rebounds to close 6% in red; SK Hynix drops 10%
WALTHAM, Mass. - TScan Therapeutics Inc. (NASDAQ:TCRX) announced today that the first patient received an infusion of TSC-101 in its phase 3 ALLOHA-2 trial. The patient, enrolled in June, received the treatment following stem cell engraftment.
The trial evaluates TSC-101 for treating residual disease to prevent relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes. The company expects topline data readout in mid-2028, according to a press release statement.
The phase 3 study compares TSC-101 administered after standard hematopoietic cell transplantation versus transplantation alone. Treatment assignment is based on biological factors, with A02:01-positive subjects who have an appropriate donor assigned to the treatment arm. A02:01-negative subjects, or A02:01-positive subjects without an appropriate donor, are assigned to the control arm.
All subjects receive hematopoietic cell transplantation with reduced intensity conditioning. Subjects in the treatment arm receive two infusions of TSC-101 following engraftment.
The primary endpoint is relapse-free survival. Key secondary endpoints include overall survival and event-free survival.
TScan is a clinical-stage biotechnology company developing T cell receptor-engineered T cell therapies for cancer treatment. TSC-101 is the company’s lead therapy candidate in development for patients with hematologic malignancies.
The trial is registered on clinicaltrials.gov with identifier NCT07702578 and is actively enrolling patients across the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
WALTHAM, Mass. - TScan Therapeutics Inc. (NASDAQ:TCRX) announced today that the first patient received an infusion of TSC-101 in its phase 3 ALLOHA-2 trial. The patient, enrolled in June, received the treatment following stem cell engraftment.
The trial evaluates TSC-101 for treating residual disease to prevent relapse after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndromes. The company expects topline data readout in mid-2028, according to a press release statement.
The phase 3 study compares TSC-101 administered after standard hematopoietic cell transplantation versus transplantation alone. Treatment assignment is based on biological factors, with A02:01-positive subjects who have an appropriate donor assigned to the treatment arm. A02:01-negative subjects, or A02:01-positive subjects without an appropriate donor, are assigned to the control arm.
All subjects receive hematopoietic cell transplantation with reduced intensity conditioning. Subjects in the treatment arm receive two infusions of TSC-101 following engraftment.
The primary endpoint is relapse-free survival. Key secondary endpoints include overall survival and event-free survival.
TScan is a clinical-stage biotechnology company developing T cell receptor-engineered T cell therapies for cancer treatment. TSC-101 is the company’s lead therapy candidate in development for patients with hematologic malignancies.
The trial is registered on clinicaltrials.gov with identifier NCT07702578 and is actively enrolling patients across the United States.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。